USC-087

• CAT Number: I037892
• Molecular Formula: C34H58N7O5P
• Molecular Weight: 675.85
• Purity: 98%
• Synonyms: USC-087; USC087; USC 087
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (4-((S)-1-amino-2-(hexadecylamino)-2-oxoethyl)benzyl)((((2S)-1-(6-amino-4,5-dihydro-9H-purin-9-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphinic acid
• InChI: InChI=1S/C34H58N7O5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20-37-34(43)30(35)28-18-16-27(17-19-28)23-47(44,45)26-46-29(22-42)21-41-25-40-31-32(36)38-24-39-33(31)41/h16-19,24-25,29-31,33,42H,2-15,20-23,26,35H2,1H3,(H,37,43)(H,44,45)(H2,36,38,39)/t29-,30-,31?,33?/m0/s1
• InChIKey: HYGAPLJVCRVKAG-NOHNHAJDSA-N
• SMILES: NC1=NC=NC2C1N=CN2C[C@@H](CO)OCP(CC3=CC=C([C@H](N)C(NCCCCCCCCCCCCCCCC)=O)C=C3)(O)=O

USC-087（Cat No.:I037892）is an experimental compound studied for its potential therapeutic applications, particularly in oncology. It acts as an inhibitor of specific enzymes or molecular targets involved in the regulation of cell growth, survival, and metastasis in cancer cells. USC-087 has shown promise in preclinical studies for its ability to suppress tumor progression and enhance the efficacy of existing cancer treatments. Its mechanism of action involves disrupting key signaling pathways that are often dysregulated in cancer. Clinical trials are underway to evaluate its safety, pharmacokinetics, and potential for use in cancer therapy.